Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Almirall, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: $2B

Website

Clinical Trials

A Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Participants with Moderate-to-Severe Atopic Dermatitis

Recruiting

Conditions: Atopic Dermatitis
Eczema

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-25

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 1000

Registration Number: NCT06815380

Locations: 🇩🇰
Aarhus University Hospital, Aarhus, Denmark

A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

Phase 3

Recruiting

Conditions: Dermatitis, Atopic
Eczema

Interventions: Biological: Lebrikizumab
Other: Placebo

First Posted Date: 2024-07-29

Last Posted Date: 2025-05-21

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 520

Registration Number: NCT06526182

Locations: 🇪🇸
Hospital General Universitario Dr. Balmis, Alicante, Spain
🇪🇸
Hospital del Mar - Parc de Salut Mar, Barcelona, Spain
🇪🇸
Hospital Universitario Clínico San Cecilio, Granada, Spain

and more 1 locations

A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting

Active, not recruiting

Conditions: Plaque Psoriasis

Interventions: Drug: Tildrakizumab

First Posted Date: 2024-07-05

Last Posted Date: 2025-06-24

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 42

Registration Number: NCT06488170

Locations: 🇨🇿
General university hospital Prague, Praha, Czechia
🇨🇿
University Hospital Bulovka, Praha, Czechia
🇨🇿
Masarykova hospital Ústí nad Labem, Ústí Nad Labem, Czechia

and more 4 locations

Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease

Phase 1

Recruiting

Conditions: Autoimmune Disease
Healthy Volunteers

Interventions: Drug: LAD191
Other: Placebo

First Posted Date: 2024-07-05

Last Posted Date: 2024-10-18

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 72

Registration Number: NCT06488209

Locations: 🇺🇸
Doral Medical Research, Miami, Florida, United States
🇺🇸
Jennifer Parish, MD, Philadelphia, Pennsylvania, United States
🇺🇸
ICON Early Phase Services, LLC, San Antonio, Texas, United States

A Single and Multiple Ascending Dose Study of LAD603 in Healthy Subjects

Phase 1

Recruiting

Conditions: Healthy Volunteers

Interventions: Drug: LAD603
Other: Placebo

First Posted Date: 2024-01-11

Last Posted Date: 2024-10-28

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 92

Registration Number: NCT06200597

Locations: 🇺🇸
ICON Phase 1 unit Lenexa, Lenexa, Kansas, United States

A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis

Phase 3

Active, not recruiting

Conditions: Keratosis, Actinic

Interventions: Drug: Tirbanibulin
Other: Vehicle ointment

First Posted Date: 2023-11-18

Last Posted Date: 2025-02-13

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 280

Registration Number: NCT06135415

Locations: 🇩🇪
Site 17, Augsburg, Germany
🇩🇪
Site 1, Bad Bentheim, Germany
🇩🇪
Site 3, Bochum, Germany

and more 32 locations

A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)

Recruiting

Conditions: Genital Psoriasis

Interventions: Drug: Tildrakizumab

First Posted Date: 2023-09-08

Last Posted Date: 2025-01-29

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 110

Registration Number: NCT06029257

Locations: 🇦🇹
Medizinische Universität Graz, Graz, Styria, Austria

A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis

Recruiting

Conditions: Plaque Psoriasis

Interventions: Drug: Tildrakizumab

First Posted Date: 2023-09-08

Last Posted Date: 2025-01-29

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 50

Registration Number: NCT06030076

Locations: 🇦🇹
Gesundheitszentrum Citypark Graz, Graz, Styria, Austria

Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

Phase 3

Active, not recruiting

Conditions: Eczema
Atopic Dermatitis

Interventions: Biological: Lebrikizumab

First Posted Date: 2023-08-14

Last Posted Date: 2025-04-24

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 240

Registration Number: NCT05990725

Locations: 🇩🇪
Site 34, Augsburg, Germany
🇩🇪
Site 9, Berlin, Germany
🇩🇪
Site 29, Bonn, Germany

and more 30 locations

Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis

Phase 3

Active, not recruiting

Conditions: Atopic Dermatitis

Interventions: Biological: Lebrikizumab

First Posted Date: 2023-06-23

Last Posted Date: 2025-05-02

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 200

Registration Number: NCT05916365

Locations: 🇩🇪
Investigator Site 7, Darmstadt, Hessen, Germany
🇩🇪
Investigator Site 8, Frankfurt, Hessen, Germany
🇩🇪
Investigator Site 9, Osnabrück, Lower Saxony, Germany

and more 29 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy